Disclaimer
The services and materials described on this website are consultancy services only, provided by Ascentra Medical (A²I™) and Aesculytics Limited.
No guarantee of outcome
Neither Ascentra Medical nor Aesculytics Limited guarantees that use of our services, tools, or Evidence Claim Strength (ECS) analysis will result in regulatory approval, reimbursement listing, investor funding, or any other commercial outcome. Regulatory and reimbursement decisions are made by independent bodies (including TGA, MHRA, FDA, MSAC, NICE, PHARMAC, and CMS) outside our control.
Not a substitute for professional advice
Nothing on this website constitutes regulatory affairs representation, legal advice, or financial/investment advice. You should seek independent regulatory, legal, clinical, and financial advice specific to your circumstances.
In silico evidence
Acceptance of in silico evidence is at the sole discretion of each regulatory or reimbursement authority. We make no guarantee that in silico evidence generated through our services will be accepted by any particular body.
Intellectual property
A²I™ ASSUMPTION INTELLIGENCE is the subject of New Zealand trade mark application 1317446 (Class 42), filed by Alia Mahgoub trading as Ascentra Medical and accepted by the Intellectual Property Office of New Zealand on 22 May 2026. The A²I™ methodology, Evidence Claim Strength framework, and Aesculytics’ in silico clinical trial models and computational frameworks remain the intellectual property of their respective owners.
A full Consultancy Services Agreement, including fees, liability terms, and confidentiality obligations, is provided directly to clients as part of a signed engagement and is not published on this website.